Biological standards in haemostasis and thrombosis

Area of Science:

• Biotechnology
• Haemostasis and Thrombosis
• Pharmaceutical Sciences

Background:

• International standards are crucial for evaluating the potency of biological drugs in haemostasis and thrombosis.
• These standards apply to critical treatments like haemophilia therapies, thrombolytics (e.g., streptokinase), and anticoagulants (e.g., heparin).
• Established standards, some over 25 years old, are vital for ensuring drug consistency and patient safety.

Purpose of the Study:

• To highlight the importance of international standards in biological drug assessment.
• To discuss the role of these standards in haemostasis and thrombosis treatments.
• To identify challenges in biological standardization due to evolving technologies.

Main Methods:

• Review of existing international standards for biological drugs.
• Analysis of drug classes including coagulation factors, thrombolytics, and anticoagulants.
• Consideration of the impact of new biotechnologies on standardization.

Main Results:

• International standards have a long history of ensuring drug potency and safety.
• These standards cover a range of essential therapeutic agents.
• The complexity of novel biological products, especially from recombinant technology, poses challenges.

Conclusions:

• International standards are indispensable for the quality control of biological medicines.
• Continued vigilance and adaptation of standards are necessary to address new biotechnological products.
• Effective biological standardization is key to maintaining therapeutic efficacy and safety in haemostasis and thrombosis.